Search results
Enliven Therapeutics COO sells over $22k in company stock By Investing.com
Investing.com· 4 hours agoEnliven Therapeutics, Inc. (NASDAQ:ELVN) has reported a recent transaction involving its Chief...
Rapport Therapeutics director buys $9.5 million in company stock By Investing.com
Investing.com· 3 hours agoDirector of Rapport Therapeutics, Inc. (NASDAQ:RAPP), James Healy, has recently made a substantial...
With 43% stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) seems to have captured institutional...
Simply Wall St. via Yahoo Finance· 9 hours agoKey Insights Significantly high institutional ownership implies Y-mAbs Therapeutics' stock price is...
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
Motley Fool via Yahoo Finance· 13 hours agoViking Therapeutics (NASDAQ: VKTX) and Madrigal Pharmaceuticals (NASDAQ: MDGL) are highly prominent...
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of “Buy” by Analysts
ETF DAILY NEWS· 1 day agoDianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has been assigned an average...
StockNews.com Downgrades ProQR Therapeutics (NASDAQ:PRQR) to Sell
ETF DAILY NEWS· 4 days agoProQR Therapeutics (NASDAQ:PRQR – Get Free Report) was downgraded by investment analysts at...
After Plunging -5.14% in 4 Weeks, Here's Why the Trend Might Reverse for Cerevel Therapeutics (CERE)
Zacks via Yahoo Finance· 13 hours agoCerevel Therapeutics (CERE) has become technically an oversold stock now, which implies exhaustion...
Has Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Impressive Stock Performance Got Anything to Do...
Simply Wall St. via Yahoo Finance· 2 days agoProtagonist Therapeutics (NASDAQ:PTGX) has had a great run on the share market with its stock up by...
It Looks Like Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO May Expect Their Salary To Be Put...
Simply Wall St. via Yahoo Finance· 5 days agoKey Insights Intellia Therapeutics will host its Annual General Meeting on 12th of June CEO John...
Halozyme Therapeutics Scores RS Rating Jump To 91
Investor's Business Daily· 3 days agoOn Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91. See if the biotech stock forms a new...